<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071486</url>
  </required_header>
  <id_info>
    <org_study_id>BU-AdultPK/PGx1</org_study_id>
    <nct_id>NCT01071486</nct_id>
  </id_info>
  <brief_title>Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation</brief_title>
  <official_title>Busulfan Pharmacokinetic Analysis and Glutathione S-transferase (GST)Genetic Polymorphism (A1,T1,M1,P1)in Adults Undergoing Hematological Bone Marrow Transplantation (HSCT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Israel Cancer Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 100 up to 200 adults undergoing HSCT for their primary disease will be included in
      this pharmacokinetic/pharmacogenetic study. In the preparative protocol Busulfan (BU)will be
      included as indicated in a known protocol. The GST polymorphism (A1,M1,T1 and P1) will be
      investigated using real time PCR. A correlation between pharmacokinetic parameters and
      patients polymorphism will be performed using known statistical technics for comparison. The
      aims of this study are, to correlate the demographic data, clinical presentation, clinical
      outcomes of the included individuals, the BU kinetics and the GST polymorphism and to
      establish an outcome &quot;map&quot; for those who receive HSCT for their primary disease.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of participants
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Veno-Occlusive Disease, Graft versus host disease</measure>
    <time_frame>every week after HSCT up to 6 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Busulfan Pharmacokinetic Analysis</condition>
  <condition>GST Genetic Polymorphism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hematological Stem Cell Transplantation</intervention_name>
    <description>Oral or Intravenous Busulfan as part of the preparative protocol for transplantation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malignant or Benign Diseases who need hematological stem cell transplantation as part
             of their treatment

          -  Busulfan should be part of the preparative protocol

        Exclusion Criteria:

          -  Known sensitivity or allergy to Busulfan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>November 8, 2015</last_update_submitted>
  <last_update_submitted_qc>November 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>N_Krivoy</investigator_full_name>
    <investigator_title>Clinical Pharmacology Unit</investigator_title>
  </responsible_party>
  <keyword>Busulfan</keyword>
  <keyword>Glutathione S-transferase</keyword>
  <keyword>Genetic polymorphism</keyword>
  <keyword>HVOD</keyword>
  <keyword>GVHD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

